A decision analysis approach to neuroleptic dosing: Insights from a mathematical model

Journal of Clinical Psychiatry

Volumn 58, Issue 2, 1997, Pages 66-73

  Mossman, Douglas ^a,b  

^a UNIVERSITY OF DAYTON   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; PROPRANOLOL; VENLAFAXINE;

ARTICLE; DEPRESSION; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MENTAL DISEASE; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 0031027145     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0203     Document Type: Article

References (43)

1. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719
2. Bollini P, Pampallona S, Orza MJ, et al. Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 1994;24:307-316
3. Kane JM, Marder SR. Psychopharmacological treatment of schizophrenia. Schizophr Bull 1993;19:287-302
4. Baldessarini RJ, Cohen BJ, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91
5. Segal SP, Cohen D, Marder SR. Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective. Am J Public Health 1992;82:846-852
6. Reardon GT, Rifkin A, Schwartz A, et al. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989;146:726-728
7. Leblanc G, Cormier HJ, Vaillancourt S, et al. Qui vent les patients traites en clinique externe avec des doses élevées de neuroleptiques? Can J Psychiatry 1990;35:12-24
8. Van Putten T, Marshall BD, Liberman R, et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993;29:315-320
9. McIntyre C, Simpson GM. How much neuroleptic is enough? Psychiatric Annals 1995;25:135-139
10. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797-805
11. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745
12. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
13. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991;48:166-170
14. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
15. Brotman AW, McCormick S III. A role for high-dose antipsychotics. J Clin Psychiatry 1990;51:164-166
16. Kahneman D, Twersky A. Judgment Under Uncertainty: Heuristics and Biases. New York, NY: Cambridge University Press; 1982
17. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia, Pa: Saunders; 1980
18. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-1117
19. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145:993-996
20. Zarate CA, Cole JO. An algorithm for the pharmacological treatment of schizophrenia. Psychiatric Annals 1994;24:333-340
21. Simpson GM, Krakov L, Mattke D, et al. A controlled comparison of the treatment of schizophrenic patients when treated according to neuroleptic or by clinical judgment. Acta Psychiatr Scand Suppl 1970;(suppl 212):38-43
22. Haase HJ, Janssen PAJ. The Actions of Neuroleptic Drugs. 2nd ed. New York, NY: Elsevier Science; 1985
23. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235
24. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950
25. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem 1974;20: 1255-1270
26. Teicher MH, Baldessarini RJ. Selection of neuroleptic dosage. Arch Gen Psychiatry 1985;42:636-637
27. Addington D. The use of placebos in clinical trials for acute schizophrenia. Can J Psychiatry 1995;40:171-176
28. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87
29. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
30. Carpenter W Jr. Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 1986;47(5, suppl):23-29
31. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
32. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993
33. DeNeef P, Kent DL. Using treatment-tradeoff preferences to select diagnostic strategies: linking the ROC curve to threshold analysis. Med Decis Making 1993;13:126-132
34. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994;55(9, suppl A):6-22
35. Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995;152:673-682
36. Levinson DF, Simpson GM, Lo E-S, et al. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 1995;152:765-771
37. Volavka J. Haloperidol dosing strategies [letter with reply]. Am J Psychiatry 1996;153:1108
38. Stone CK, Garver DL. Haloperidol dosing strategies [reply letter]. Am J Psychiatry 1996;153:1109
39. Hoge SK, Feucht-Haviar TC. Long-term, assenting psychiatric patients: decisional capacity and the quality of care. Bull Am Acad Psychiatry Law 1995;23:343-352
40. Dawes RM, Faust D, Meehl PE. Clinical versus actuarial judgment. Science 1989;243:1668-1674
41. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995;152:698-703
42. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
43. Livingstone MG. Risperidone. Lancet 1994;343:457-460